Article

Phase II Exploratory Study of Neoadjuvant Disitamab Vedotin and Penpulimab in HER2-low Stage II-III Breast Cancer (NeoPanDa04)

2025-12-01

Abstract excerpt

<title>Abstract</title> <p>HER2-low breast cancer lacks effective targeted options in the curative setting. We evaluated the efficacy, safety, and exploratory biomarker correlates of neoadjuvant disitamab vedotin (HER2-targeted antibody–drug conjugate) plus penpulimab (PD-1 inhibitor) in stage Ⅱ–Ⅲ disease (NCT05726175). In a prospective single-arm study, patients with newly diagnosed stage II–III HER2-low breast...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: eb6e9c93-bd6d-5b07-9f0e-4147116410ab
DOI: 10.21203/rs.3.rs-7869437/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Phase II Exploratory Study of Neoadjuvant Disitamab Vedotin and Penpulimab in HER2-low Stage II-III Breast Cancer (NeoPanDa04)DOI 10.21203/rs.3.rs-7869437/v1Read

Evaluation of RC48-ADC in combination with PRaG regimen: An open-label, prospective, multicentre study assessing efficacy and safety for advanced refractory HER2-expressing solid tumors (PRaG3.0 Study Protocol)Semantic proximity Read

Real-World Outcomes of Subcutaneous PHESGO® in HER2-Positive Breast Cancer: Pathological Response, Se-Quencing, and SafetySemantic proximity Read

A phase Ib trial evaluating the safety, efficacy, and immunologic effects of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancerSemantic proximity Read

S100A8/A9 predicts triple-negative breast cancer response to PIM kinase and PD-1/PD-L1 inhibitionSemantic proximity Read

Low and Ultra-Low HER2 in Human Breast Cancer: An Effort to Define New Neoplastic Subtypes.Semantic proximity Read

Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response.Semantic proximity Read

Low and Ultra-low HER2 in Human Breast Cancer: An Effort to Define New Neoplastic SubtypesSemantic proximity Read

Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.Semantic proximity Read

Comparison of Targeted Therapy Efficacy in HER2-Positive Versus HER2-Negative Breast Cancer PatientsSemantic proximity Read

Comparative biomarker analysis of PALOMA-2/3 trials for palbociclibSemantic proximity Read

Long-term survival after neoadjuvant low-dose ipilimumab plus high-dose nivolumab in resectable stage III melanoma: the 5-year survival-update and biomarker analysis from the PRADO-trialSemantic proximity Read

NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.Semantic proximity Read